Correspondingly, there are several clinically available PD1/PD-L1 inhibitors approved by FDA for cancer treatment ranging from melanoma to NSCLC, including but not restricted to pembrolizumab, nivolumab, atezolizumab, and avelumab. The gene discussed is CD274; the disease is melanoma.